Influenza virus in the US affects the costs of medical care, loss of work productivity, and deaths which are the outstanding impacts on the socio-economic factors during the season. The socio-economic factors are very essential for influenza control and therefore, the population affected by the virus need to be prepared for their health interventions. It was estimated that the influenza virus medical costs accounts for approximately 3 billion dollars. On an average of over two hundred thousand people are hospitalized every year and 23,000 of the population die due to respiratory and circulatory complications accompanied with seasonal influenza virus infections. Statistical regression models were used to observe the influenza virus impact in the United States.
Majority of the population in the United States do not consider the virus as alarming and also do not believing that the vaccine works. In the US consumers consider a basket of goods as very essential in the flu season. Women find more products essential than men during flu season such as cough, cold medications, facial tissues and hand sanitisers, and others products to maintaining their health and control their symptoms. More women consider such products more essential than men. The severity of the influenza virus is estimated by the availability and utilisation of the influenza vaccine, and the type of vaccine available. Every spring, the World Health Organization (WHO) collects influenza virus samples from around the world and develops the upcoming season’s vaccine. Inactivated influenza vaccines (IIV) and live attenuated vaccines (LAIV) are the two types of vaccine available in the United States.
According to the study “Disease Snapshot: Consumer Impact of Seasonal Influenza in the US”, the sales of cough, cold and allergy products (CCAs) are very high when the government provided influenza vaccine is less effective. Vitamins and dietary supplements are the other products used during the flu season for prevention along with the combination CCAs and nasal sprays for fevers and coughs, and tissue products for nasal congestion. Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Weight Management and Wellbeing are few of the necessary products for the population affected with the influenza virus.
The increased technological advancements in medical diagnostics is an indication of technology based, cost-effective devices in the diagnostic industry. Majority of the manufacturers are focusing on developing new-generation POC influenza tests such as LoC/microchip technology based on micro-electromechanical system (MEMS) that adapts biological and chemical applications. However, sophisticated influenza virus tests are available only in specialized laboratories across the globe.
To measure the efficacy and acceptability of a product for a consumer for any diagnostic tests, it is highly recommended to analysing the product safety features. This is to ensure that the product is suitable for the consumers with international standards. The leading regulatory organizations that deal with the product safety are Alere, BD, Quidel, bioMrieux, CorisBioconcept, Meridian Bioscience, Response Biomedical (acquired by OrbiMed), Princeton BioMeditech Corporation, SA Scientific, Sekisui Diagnostics, and Thermo Fisher Scientific. These organizations give clearance to the manufacturers to display specific mark that is accepted in particular countries.
The influenza virus vaccinations are manufactured in hundreds of million doses within a very short time period to meet the needs of the affected population in the US. An emergence innovative production of a vaccine system based on mammalian or insect cell cultures has answered many questions and hurdles associated with the egg-based production system. Such industrially well-established production systems provide more flexible and quick response to pandemic threats such as influenza virus. It was analysed that there is a need for developing alternative vaccine production systems based on plants, bacteria, yeast and cell cultures. The influenza virus vaccines account for about 80% of the market while the remaining are for therapeutics which is the fastest growing market aforementioned flu virus analysis period. It was estimated that the influenza virus therapeutics market will witness a positive growth during the affected season.
Related Reports
Seasonal Influenza Vaccines-Current and Future Players
Seasonal Influenza Vaccines-US Drug Forecast and Market Analysis to 2025
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
0124-4230204
